Cidara Therapeutics (CDTX) Operating Income: 2017-2025
Historic Operating Income for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to -$88.6 million.
- Cidara Therapeutics' Operating Income fell 409.53% to -$88.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$195.5 million, marking a year-over-year decrease of 49.64%. This contributed to the annual value of -$176.1 million for FY2024, which is 550.78% down from last year.
- Per Cidara Therapeutics' latest filing, its Operating Income stood at -$88.6 million for Q3 2025, which was down 223.65% from -$27.4 million recorded in Q2 2025.
- In the past 5 years, Cidara Therapeutics' Operating Income registered a high of $14.2 million during Q3 2022, and its lowest value of -$96.0 million during Q2 2024.
- Over the past 3 years, Cidara Therapeutics' median Operating Income value was -$17.4 million (recorded in 2024), while the average stood at -$30.4 million.
- Its Operating Income has fluctuated over the past 5 years, first spiked by 178.68% in 2022, then slumped by 1,322.41% in 2024.
- Over the past 5 years, Cidara Therapeutics' Operating Income (Quarterly) stood at -$16.8 million in 2021, then rose by 19.58% to -$13.5 million in 2022, then spiked by 35.49% to -$8.7 million in 2023, then plummeted by 522.71% to -$54.2 million in 2024, then slumped by 409.53% to -$88.6 million in 2025.
- Its last three reported values are -$88.6 million in Q3 2025, -$27.4 million for Q2 2025, and -$25.3 million during Q1 2025.